Diabetic Foot Ulcer Biologics Market Size and Share 2034
Diabetic Foot Ulcer Biologics Market Growth, Size, Trends Analysis - By Product, By Indication, By End-User - Regional Outlook, Competitive Strategies and Segment Forecast to 2034
| Published: Sep-2025 | Report ID: HLCA25293 | Pages: 1 - 241 | Formats*: |
| Category : Healthcare | |||
Diabetic Foot Ulcer Biologics Market Introduction and Overview
According to SPER Market Research, the Global Diabetic Foot Ulcer Biologics Market is estimated to reach USD 4.93 billion by 2034 with a CAGR of 8.15%.
The report includes an in-depth analysis of the Global Diabetic Foot Ulcer Biologics Market, including market size and trends, product mix, Applications, and supplier analysis. The global market for Diabetic Foot Ulcer Biologics was valued at approximately USD 2.25 billion in 2024 and is anticipated to expand at a compound annual growth rate (CAGR) of 8.15% from 2025 to 2034. The increased frequency of Diabetic Foot Ulcer (DFU) cases, as well as advances in biologic technology focused at treating this illness, are driving up demand for diabetic foot ulcer biologics. Furthermore, the expanding older population, which is more susceptible to such illnesses, contributes significantly to market growth.
By Product Insights:
The skin substitutes segment led the market in 2024, capturing the largest revenue share within the product category. This segment's growth is fueled by robust clinical evidence that validates their efficacy in treating diabetic foot ulcers (DFUs). Meanwhile, the tissue-engineered products market is expected to expand the fastest, driven by the rising prevalence of diabetes and its comorbidities, particularly diabetic foot ulcers, as well as increased demand for innovative wound-healing therapies. Products such as Apligraf have shown promising results in the treatment of diabetic foot ulcers.
By Indication Insights:
The neuro-ischemic ulcers category dominated the market in 2024. The segment's growth is being driven by an increasing emphasis on evaluating various types of biologics, such as skin replacements and growth factors, for the treatment of neuro-ischemic ulcers. Furthermore, the ischaemic diabetic foot ulcer segment is expected to grow at the fastest compound annual growth rate (CAGR) during the forecast period, owing to the rising prevalence of peripheral arterial disease among diabetic patients, which is a major contributor to the development of ischaemic ulcers.
By End-User Insights:
The hospital category also held the biggest market share in 2024 and is predicted to rise significantly during the forecast period. Hospitals play a critical role in the use of biologics for diabetic foot ulcers, and their increased acceptance is expected to drive market growth in the future. Hospital facilities are preferred over alternative healthcare settings because they provide complete care to individuals with complex medical needs. They have the medical knowledge, infrastructure, and resources to efficiently manage and monitor patients' health, resulting in best treatment outcomes. Furthermore, hospitals can offer fast access to advanced medical care in the event of difficulties or crises. These hospital-related benefits are expected to drive segment growth in the coming years.
Regional Insights:
North America held the biggest revenue share in the diabetic foot ulcer biologics market in 2024. This market leadership is fueled by heightened awareness regarding the necessity of prompt and effective wound care, alongside the increasing prevalence of chronic conditions like diabetes that can result in diabetic foot ulcers. Additionally, North America hosts prominent pharmaceutical firms and research institutions that foster innovation in biologic therapies, including growth factors and tissue-engineered solutions.
Market Competitive Landscape:
The market for diabetic foot ulcer biologics is dominated by companies such as Coloplast Group (Kerecis), MIMEDX Group, Inc., Integra LifeSciences, Tissue Regenix, BioTissue, and Convatec Inc. These businesses are expanding their diabetic foot ulcer biologics portfolio in order to get a competitive advantage in the years to come. In addition, industry players are aggressively launching new goods to meet the growing need for biologics in the management of diabetic foot ulcers.
Recent Developments:
In January 2025, BioStem Technologies initiated a clinical trial to assess the therapeutic advantages of its BioREtain technology in the treatment of diabetic foot ulcers (DFUs) utilizing Vendaje. The experiment aims to assess the efficacy of routine therapy with and without Vendaje, an amniotic membrane product, in patients with non-healing DFUs. The study will evaluate the influence of Vendaje on wound closure rates, aiming to establish its superiority in advanced wound care and enhance its market acceptance.
In February 2024, Technophage, a biopharmaceutical company dedicated to the development and production of biologics, especially bacteriophage-based products, announced the successful administration of the first dose to a patient in a crucial phase of its trial. This study seeks to assess the effectiveness of TP-102 in treating diabetic foot ulcers infected by Staphylococcus aureus, Pseudomonas aeruginosa, and Acinetobacter baumannii.
Scope of the report:
| Report Metric | Details |
| Market size available for years | 2021-2034 |
| Base year considered | 2024 |
| Forecast period | 2025-2034 |
| Segments covered | By Product, By Indication, By End-User |
| Regions covered | North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa |
| Companies Covered | Organogenesis Holdings Inc, Tissue Regenix, BioTissue, Integra LifeSciences, MIMEDX Group, Inc, Convatec Inc, Coloplast Group (Kerecis), Biocomposites, Smith+Nephew, Inc, Stedical Scientific, Inc. |
- Global Diabetic Foot Ulcer Biologics Market Size (FY 2021-FY 2034)
- Overview of Global Diabetic Foot Ulcer Biologics Market
- Segmentation of Global Diabetic Foot Ulcer Biologics Market By Product (Skin Substitutes, Growth Factors, Tissue-Engineered Products)
- Segmentation of Global Diabetic Foot Ulcer Biologics Market By Indication (Neuro-ischemic Ulcers, Neuropathic Diabetic Foot Ulcer, Ischemic Diabetic Foot Ulcer)
- Segmentation of Global Diabetic Foot Ulcer Biologics Market By End-User (Hospitals, Clinics, Ambulatory Surgical Centers, Long-Term Care Settings, Others)
- Statistical Snap of Global Foot Ulcer Biologics Market
- Expansion Analysis of Global Foot Ulcer Biologics Market
- Problems and Obstacles in Global Foot Ulcer Biologics Market
- Competitive Landscape in the Global Foot Ulcer Biologics Market
- Details on Current Investment in Global Foot Ulcer Biologics Market
- Competitive Analysis of Global Foot Ulcer Biologics Market
- Prominent Players in the Global Foot Ulcer Biologics Market
- SWOT Analysis of Global Foot Ulcer Biologics Market
- Global Foot Ulcer Biologics Market Future Outlook and Projections (FY 2025-FY 2034)
- Recommendations from Analyst
1. Introduction
- 1.1. Scope of the report
- 1.2. Market segment analysis
2. Research Methodology
- 2.1. Research data source
- 2.1.1. Secondary Data
- 2.1.2. Primary Data
- 2.1.3. SPERs internal database
- 2.1.4. Premium insight from KOLs
- 2.2. Market size estimation
- 2.2.1. Top-down and Bottom-up approach
- 2.3. Data triangulation
3. Executive Summary
4. Market Dynamics
- 4.1. Driver, Restraint, Opportunity and Challenges analysis
- 4.1.1. Drivers
- 4.1.2. Restraints
- 4.1.3. Opportunities
- 4.1.4. Challenges
5. Market variable and outlook
- 5.1. SWOT Analysis
- 5.1.1. Strengths
- 5.1.2. Weaknesses
- 5.1.3. Opportunities
- 5.1.4. Threats
- 5.2. PESTEL Analysis
- 5.2.1. Political Landscape
- 5.2.2. Economic Landscape
- 5.2.3. Social Landscape
- 5.2.4. Technological Landscape
- 5.2.5. Environmental Landscape
- 5.2.6. Legal Landscape
- 5.3. PORTERs Five Forces
- 5.3.1. Bargaining power of suppliers
- 5.3.2. Bargaining power of buyers
- 5.3.3. Threat of Substitute
- 5.3.4. Threat of new entrant
- 5.3.5. Competitive rivalry
- 5.4. Heat Map Analysis
6. Competitive Landscape
- 6.1. Global Diabetic Foot Ulcer Biologics Market Manufacturing Base Distribution, Sales Area, Product Type
- 6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Diabetic Foot Ulcer Biologics Market
7. Global Diabetic Foot Ulcer Biologics Market, By Product (USD Million) 2021-2034
- 7.1. Skin Substitutes
- 7.1.1. Biological
- 7.1.2. Synthetic
- 7.1.3. Bio-Synthetic
- 7.2. Growth Factors
- 7.3. Tissue-Engineered Products
8. Global Diabetic Foot Ulcer Biologics Market, By Indication (USD Million) 2021-2034
- 8.1. Neuro-ischemic Ulcers
- 8.2. Neuropathic Diabetic Foot Ulcer
- 8.3. Ischemic Diabetic Foot Ulcer
9. Global Diabetic Foot Ulcer Biologics Market, By End-User (USD Million) 2021-2034
- 9.1. Hospitals
- 9.2. Clinics
- 9.3. Ambulatory Surgical Centers (ASCs)
- 9.4. Long-Term Care Settings
- 9.5. Others
10. Global Diabetic Foot Ulcer Biologics Market, (USD Million) 2021-2034
- 10.1. Global Diabetic Foot Ulcer Biologics Market Size and Market Share
11. Global Diabetic Foot Ulcer Biologics Market, By Region, (USD Million) 2021-2034
- 11.1. Asia-Pacific
- 11.1.1. Australia
- 11.1.2. China
- 11.1.3. India
- 11.1.4. Japan
- 11.1.5. South Korea
- 11.1.6. Rest of Asia-Pacific
- 11.2. Europe
- 11.2.1. France
- 11.2.2. Germany
- 11.2.3. Italy
- 11.2.4. Spain
- 11.2.5. United Kingdom
- 11.2.6. Rest of Europe
- 11.3. Middle East and Africa
- 11.3.1. Kingdom of Saudi Arabia
- 11.3.2. United Arab Emirates
- 11.3.3. Qatar
- 11.3.4. South Africa
- 11.3.5. Egypt
- 11.3.6. Morocco
- 11.3.7. Nigeria
- 11.3.8. Rest of Middle-East and Africa
- 11.4. North America
- 11.4.1. Canada
- 11.4.2. Mexico
- 11.4.3. United States
- 11.5. Latin America
- 11.5.1. Argentina
- 11.5.2. Brazil
- 11.5.3. Rest of Latin America
12. Company Profile
- 12.1. Organogenesis Holdings Inc
- 12.1.1. Company details
- 12.1.2. Financial outlook
- 12.1.3. Product summary
- 12.1.4. Recent developments
- 12.2. Tissue Regenix
- 12.2.1. Company details
- 12.2.2. Financial outlook
- 12.2.3. Product summary
- 12.2.4. Recent developments
- 12.3. BioTissue
- 12.3.1. Company details
- 12.3.2. Financial outlook
- 12.3.3. Product summary
- 12.3.4. Recent developments
- 12.4. Integra LifeSciences
- 12.4.1. Company details
- 12.4.2. Financial outlook
- 12.4.3. Product summary
- 12.4.4. Recent developments
- 12.5. MIMEDX Group, Inc
- 12.5.1. Company details
- 12.5.2. Financial outlook
- 12.5.3. Product summary
- 12.5.4. Recent developments
- 12.6. Convatec Inc
- 12.6.1. Company details
- 12.6.2. Financial outlook
- 12.6.3. Product summary
- 12.6.4. Recent developments
- 12.7. Coloplast Group (Kerecis)
- 12.7.1. Company details
- 12.7.2. Financial outlook
- 12.7.3. Product summary
- 12.7.4. Recent developments
- 12.8. Biocomposites
- 12.8.1. Company details
- 12.8.2. Financial outlook
- 12.8.3. Product summary
- 12.8.4. Recent developments
- 12.9. Smith+Nephew, Inc.
- 12.9.1. Company details
- 12.9.2. Financial outlook
- 12.9.3. Product summary
- 12.9.4. Recent developments
- 12.10. Stedical Scientific, Inc
- 12.10.1. Company details
- 12.10.2. Financial outlook
- 12.10.3. Product summary
- 12.10.4. Recent developments
- 12.11. Others
13. Conclusion
14. List of Abbreviations
15. Reference Links
SPER Market Research’s methodology uses great emphasis on primary research to ensure that the market intelligence insights are up to date, reliable and accurate. Primary interviews are done with players involved in each phase of a supply chain to analyze the market forecasting. The secondary research method is used to help you fully understand how the future markets and the spending patterns look likes.
The report is based on in-depth qualitative and quantitative analysis of the Product Market. The quantitative analysis involves the application of various projection and sampling techniques. The qualitative analysis involves primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes are validated through experts opinion. Our research methodology entails an ideal mixture of primary and secondary initiatives.
Frequently Asked Questions About This Report
Diabetic Foot Ulcer Biologics Market is projected to reach USD 6.77 billion by 2034, growing at a CAGR of of 8.15% during the forecast period.
Diabetic Foot Ulcer Biologics Market grew in Market size from 2025. The Market is expected to reach USD 6.77 billion by 2034, at a CAGR of 8.15% during the forecast period.
Diabetic Foot Ulcer Biologics Market CAGR of 8.15% during the forecast period.
You can get the sample pages by clicking the link - Click Here
Diabetic Foot Ulcer Biologics Market size is USD 6.77 billion from 2025 to 2034.
Diabetic Foot Ulcer Biologics Market is covered By Product, By Indication, By End-User
The North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa is the highest Market share in the Diabetic Foot Ulcer Biologics Market.
Organogenesis Holdings Inc, Tissue Regenix, BioTissue, Integra LifeSciences, MIMEDX Group, Inc, Convatec Inc, Coloplast Group (Kerecis), Biocomposites, Smith+Nephew, Inc, Stedical Scientific, Inc.
The report includes an in-depth analysis of the Global Diabetic Foot Ulcer Biologics Market, including market size and trends, product mix, Applications, and supplier analysis.
PLACE AN ORDER
Year End Discount
Sample Report
Pre-Purchase Inquiry
NEED CUSTOMIZATION?
Request CustomizationCALL OR EMAIL US
100% Secure Payment
Related Reports
Have a glance of the Report
Our Global Clients
Our data-driven insights have influenced the strategy of 200+ reputed companies across the globe.
